1 recruiting, 1 suspended, 1 withdrawn. 1 Early Phase 1, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Suspended 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow CD30+ Peripheral T-cell Lymphoma: new trials by email Literature Review of CD30+ Peripheral T-cell Lymphoma trials Research Report on CD30+ Peripheral T-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD30 CAR-T in the Treatment of CD30 Positive Lymphoma chimeric antigen receptor gene modified T cells - Lymphoma, B Cell Lymphoma | Early Phase 1 | Suspended | Shandong Qilu Cell Therapy Engineering Technology Co., Ltd | 15 | 2026-03-01 | 2026-09-28 |
| Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide), Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide), Maintenance therapy-chidamide - CD30+ Peripheral T-cell Lymphoma | Not applicable | Recruiting | The First Affiliated Hospital of Soochow University | 47 | 2024-11-01 | 2025-07-20 |
| Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas Brentuximab Vedotin, TAK228, Glucose Monitor - Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Classical Hodgkin Lymphoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2018-03-01 | 2018-01-17 |
Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Lymphoma (1) · Lymphoma, T-Cell (1)
Brentuximab Vedotin (2) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · sapanisertib (1)
M.D. Anderson Cancer Center (1) · Shandong Qilu Cell Therapy Engineering Technology Co., Ltd (1) · The First Affiliated Hospital of Soochow University (1)
China (2)